Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 53,544 | 57,622 | 58,766 | 62,472 | 57,336 |
| Cost of Goods | 12,290 | 12,535 | 9,383 | 9,919 | 7,625 |
| Gross Profit | 41,254 | 45,087 | 49,383 | 52,553 | 49,711 |
| Operating Expenses | 46,240 | 54,175 | 45,317 | 39,383 | 36,822 |
| Operating Income | -4,696 | -8,553 | 4,449 | 14,089 | 13,514 |
| Interest Expense | 4,691 | 4,827 | 4,748 | 6,834 | 7,770 |
| Other Income | 459 | 2,145 | 1,454 | -7,008 | 368 |
| Pre-tax Income | -8,928 | -11,235 | 1,155 | 247 | 6,112 |
| Income Tax | 126 | 1,009 | 615 | N/A | N/A |
| Net Income Continuous | -9,054 | -12,244 | 540 | 247 | 6,112 |
| Net Income | $-9,054 | $-12,244 | $540 | $247 | $6,112 |
| EPS Basic Total Ops | -0.03 | -0.05 | 0.00 | 0.00 | 0.03 |
| EPS Basic Continuous Ops | -0.03 | -0.05 | 0.00 | 0.00 | 0.03 |
| EPS Diluted Total Ops | -0.03 | -0.05 | 0.00 | 0.00 | 0.03 |
| EPS Diluted Continuous Ops | -0.03 | -0.05 | 0.00 | 0.00 | 0.03 |
| EPS Diluted Before Non-Recurring Items | -0.03 | -0.05 | 0.00 | 0.00 | 0.03 |
| EBITDA(a) | $-4,368 | $-8,232 | $4,767 | $14,405 | $13,828 |